These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
491 related articles for article (PubMed ID: 17696798)
1. PEG-asparaginase. Fu CH; Sakamoto KM Expert Opin Pharmacother; 2007 Aug; 8(12):1977-84. PubMed ID: 17696798 [TBL] [Abstract][Full Text] [Related]
2. Pegasparaginase: where do we stand? Zeidan A; Wang ES; Wetzler M Expert Opin Biol Ther; 2009 Jan; 9(1):111-9. PubMed ID: 19063697 [TBL] [Abstract][Full Text] [Related]
3. Pegaspargase: a review of clinical studies. Graham ML Adv Drug Deliv Rev; 2003 Sep; 55(10):1293-302. PubMed ID: 14499708 [TBL] [Abstract][Full Text] [Related]
4. [Therapeutic alternatives to native L-asparaginase in the treatment of adult acute lymphoblastic leukemia]. Thomas X; Cannas G; Chelghoum Y; Gougounon A Bull Cancer; 2010 Sep; 97(9):1105-17. PubMed ID: 20693115 [TBL] [Abstract][Full Text] [Related]
5. Pharmacological and clinical evaluation of L-asparaginase in the treatment of leukemia. Narta UK; Kanwar SS; Azmi W Crit Rev Oncol Hematol; 2007 Mar; 61(3):208-21. PubMed ID: 17011787 [TBL] [Abstract][Full Text] [Related]
6. [Advances on the role of pegaspargase in the treatment of childhood leukemia]. Liu L; Xie XT Zhongguo Dang Dai Er Ke Za Zhi; 2014 Feb; 16(2):155-60. PubMed ID: 24568909 [TBL] [Abstract][Full Text] [Related]
7. Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL. Appel IM; Pinheiro JP; den Boer ML; Lanvers C; Reniers NC; Boos J; Pieters R Leukemia; 2003 Nov; 17(11):2254-6. PubMed ID: 14523472 [No Abstract] [Full Text] [Related]
8. Asparaginase treatment in infants with acute lymphoblastic leukemia; pharmacokinetics and asparaginase hypersensitivity in Interfant-06. Albertsen BK; Harila-Saari A; Jahnukainen K; Lähteenmäki P; Riikonen P; Möttönen M; Lausen B Leuk Lymphoma; 2019 Jun; 60(6):1469-1475. PubMed ID: 30632847 [TBL] [Abstract][Full Text] [Related]
9. Outcome of pediatric patients with acute lymphoblastic leukemia/lymphoblastic lymphoma with hypersensitivity to pegaspargase treated with PEGylated Erwinia asparaginase, pegcrisantaspase: A report from the Children's Oncology Group. Rau RE; Dreyer Z; Choi MR; Liang W; Skowronski R; Allamneni KP; Devidas M; Raetz EA; Adamson PC; Blaney SM; Loh ML; Hunger SP Pediatr Blood Cancer; 2018 Mar; 65(3):. PubMed ID: 29090524 [TBL] [Abstract][Full Text] [Related]
10. Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia. Hawkins DS; Park JR; Thomson BG; Felgenhauer JL; Holcenberg JS; Panosyan EH; Avramis VI Clin Cancer Res; 2004 Aug; 10(16):5335-41. PubMed ID: 15328169 [TBL] [Abstract][Full Text] [Related]
15. Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia. Hak LJ; Relling MV; Cheng C; Pei D; Wang B; Sandlund JT; Rubnitz J; Pui CH Leukemia; 2004 Jun; 18(6):1072-7. PubMed ID: 15057247 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic and pharmacodynamic properties of calaspargase pegol Escherichia coli L-asparaginase in the treatment of patients with acute lymphoblastic leukemia: results from Children's Oncology Group Study AALL07P4. Angiolillo AL; Schore RJ; Devidas M; Borowitz MJ; Carroll AJ; Gastier-Foster JM; Heerema NA; Keilani T; Lane AR; Loh ML; Reaman GH; Adamson PC; Wood B; Wood C; Zheng HW; Raetz EA; Winick NJ; Carroll WL; Hunger SP J Clin Oncol; 2014 Dec; 32(34):3874-82. PubMed ID: 25348002 [TBL] [Abstract][Full Text] [Related]
17. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL). Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659 [TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations: the past, the present and recommendations for the future. Avramis VI; Panosyan EH Clin Pharmacokinet; 2005; 44(4):367-93. PubMed ID: 15828851 [TBL] [Abstract][Full Text] [Related]